

References

REFERENCES

- 1-P. B. Molinoff, R. W. Ruddon, A. G. Gilman, eds, McGraw-Hill. New York, 617, **1996**.
- 2-A. Gamer and J. Scand, Gastroenterol, 27, 83, **1992**.
- 3-D. R. Lichtenstein, S. Syngal and M. M. Wolfe, Arthritis Rheum., 38, 5, **1995**.
- 4-J. M. Cash and J. H. Klippel, New Engl. J. Med., 330, 1368, **1994**.
- 5-N. M. Devies and J. L. J. Wallace, Gastroenterol., 32, 127, **1997**.
- 6-J. Wallace, Gastroenterol, 112, 1000, **1997**.
- 7-C. J. Shorrock, M. J. Langman, Dig. Dis., 13, 3, **1995**.
- 8-G. Singh, G. L. Triadafilopoulus, Rheumatol, 26, 18, **1999**.
- 9-M. M. Wolfe, D. R. Lichtenstein and G. Singh, New Engl. J. Med., 340, 1888, **1999**.
- 10-E. E. Batchlor and H. E. Paulus., Principles of drug therapy. In.R.w. Moskowitz, D. S. Howe, V. M. Goldberg and H. J. Mankin, eds. Osteoarthritis and Medical Surgical Management. Philadelphia, PA. WB Saunders Co, 465, **1993**.
- 11-P. M. Brooks and R. O. Day, New Engl. J. Med. 324, 1716, **1991**.
- 12-A. Miyajama, K. Ito, A. Ueda, K. J. Hayakawa, J. Urol., 166,1224, **2001**.
- 13-M. Joussen, V. Poulaki, N. Mitsiades, B. Kirchof, K. Koizumy, A. A. Sand, J. FASEB, 16, 438, **2002**.
- 14-J. L. McGuire, Pharmaceutical Classes, Therapeutic Agents and Areas of Application, Weily-VCH, Volume 2, Federal Republic of Germany, p.342, **2000**.
- 15-A. S. Amin, J. Pharma. Biomed. Anal., 29, 729, **2002**.
- 16-M. H. Abd el Hay, M. A. Korany, M. M..Bedair A. A.Gazy, Anal. Lett., 23, 281, **1990**.
- 17-M. A. Amin, F. M. Salama, S. E. Barakat, O. I. Abd Al Stattar, M. W. I. Nassar, H. H. M. Abou Seade, Egyptian J. Pharma. Sci., 37, 157, **1996**.
- 18-A. Tehseen, N. Fouzia, K. A. Ahmed, K. I. Ullah, K. M. Akram, Anal. Lett.,35, 1007, **2002**.
- 19-K. Basavaiah, H. C. Prameela, Acta Ciencia Indica, Chemistry, 27, 195, **2001**.
- 20-H. Salem, K. Khadiga, S. Abdalla. Sci. Pharmaceutica, 69, 189, **2001**.
- 21-G. Soledad, S. Concepcion, A. Isabel, G. Concepcion, Mikrochim. Acta, 136, 67, **2001**.
- 22-J. A. Arancibia, M. A. Boldrini, G. M. Escandar, Talanta, 52, 261, **2000**.
- 23-A. M. Pimenta, A. N. Araujo, M. C. B. S. M. Montenegro, Anal. Chim. Acta, 470, 185, **2002**.

- 24-P. C. Damiani, M. Bearzotti, M. A. Cabezon, J. Pharma. Biomed. Anal., 25, 679, **2001**.
- 25-T. R. S. M. Satheesh, C. D. Wali, S. S. Kadam, R. S. Dhaneshwar, Indian Drugs, 38, 564, **2001**.
- 26-C. Reguera, C. M. Ortiz, J. Arcos, Quimica Analitica, 18, 105, **1999**.
- 27-D. E. Moore, K. A. Ghebremeskel, B. B. C. Chen, E. Y. L. Wong, Photochemistry and Photobiology, 68, 685, **1998**.
- 28-R. I. El-Bagary, Egypt. Bulletin of the Faculty of Pharmacy (Cairo University), 38, 67, **2000**.
- 29-I. U. Khan, T. Aman, A. Ashraf; A. A. Kazi, Anal. Lett., 32, 2035, **1999**.
- 30-M. D. Borraccetti, A. C. Olivieri, Anal. Chim. Acta, 471, 87, **2002**.
- 31-P. Damiani, B. Patricia, C. Mariela, A. Miguel, J. Pharma. Biomed. Anal., 29, 229, **2002**.
- 32-J. A. Arancibia, G. M. Escandar, Analyst, 126, 917, **2001**.
- 33-G. Foetsch, S. Pfeifer, Pharmazie, 45, 535, **1990**.
- 34-C. Sanchez-Pedreno, M. Albero, J. M. Gimenez, J. Pharma. Biomed. Anal., 21, 731, **1999**.
- 35-M. A. El-Ries, G. Mohamed, S. Khalil, M. El-Shall, Egypt CHEMICAL AND PHARMACEUTICAL BULLETIN, 51, 6, **2003**.
- 36-M. A. El-Ries, Anal. Lett., 31, 793, **1998**.
- 37-S. Agatonovic-Kustrin, L. Zivanovic, D. Radulovic, M. Vasiljevic, Talanta, 38, 1347, **1991**.
- 38-D. M. Shingbal, U. C. Naik, India. Indian Drugs, 34, 608, **1997**.
- 39-A. Navalon, R. Blanc, M. del-Olmo, J. L. Vilchez, Talanta, 48, 469, **1999**.
- 40-I. Singhvi, S. C. Chaturvedi, Indian-drugs, 35, 234, **1998**.
- 41-Z. Atkosar, G. Altiocka, E. Goksel, G. Bulent, Acta Pharmaceutica Turcica, 43, 143, **2001**.
- 42-R. Suedee, T. Srichana, J. Saelim, T. Thavonpibulbut, J. Planar Chromatography-Modern TLC, 14, 194, **2001**.
- 43-L. I. Bebawy and N. M. El Kousy, J. Pharm. Biomed. Anal., 20, 663, **1999**.
- 44-L. G. Lala, P. M. D'Mello, S. R. Naik, J. Pharma. Biomed. Anal., 29(3), 539, **2002**.
- 45-Y. Sun, K. Takaba, H. Kido, M. N. Nakashima, K. Nakashima, J. Pharma. & Biomed. Anal., 30, 1611, **2003**.

- 46-J. Joseph-Charles, M. Bertucat, *Journal of Liquid Chromatography & Related Technologies*, 22, 2009, **1999**.
- 47-T. Hirai, S. Matsumoto, I. Kishi, *J. Chromatogr. B: Biomedical Sciences and Applications*, 692, 375, **1997**.
- 48-A. O. Van, W. Baeyens, H. Oda, H. Y. Aboul-Enein, *Chromatographia*, 43, 599, **1996**.
- 49-M. J. Thomason, Y. F. Hung, W. Rhys-Williams, G. W. Hanlon and A. W. Lloyd, *J. Pharm. Biomed. Anal.*, 15, 1765, **1997**.
- 50-M. J. Martin, F. Pablos and A. G. Gonzalez, *Talanta*, 49, 453, **1999**.
- 51-E. Mikami, T. Goto, T. Ohno, H. Matsumoto and M. Nishida, *J. Pharm. Biomed. Anal.*, 23, 917, **2000**.
- 52-N. Mano, A. Nikaido, T. Narui, D. Yamasaki, J. Goto, *J. Chromatogr. B: Analytical Technologies in the Biomedical and Life Sciences*, 776, 125, **2002**.
- 53-Z. Wang, R. M. Dsida and M. J. Avram, *J. Chromatogr. A*, 755, 383, **2001**.
- 54-H. Y. Aboul-enein, *J. Sep. Sci.*, 26, 521, **2003**.
- 55-L. Escuder-Gilabert, Y. Martin-Biosca, S. Sagrado, R. M. Villanueva-Camanas, M. J. Medina-Hernandez, *Chromatographia*, 55, 283, **2002**.
- 56-A. De Rossi, C. Desiderio, *J. Chromatogr. A*, 984, 283, **2003**.
- 57-C. Mardones, A. Rios, M. Valcarcel, *Electrophoresis*, 22, 484, **2001**.
- 58-S. Tosaksiri, D. L. Massart and Y. Vander Heyden, *Anal. Chim. Acta*, 419, 29, **2000**.
- 59-J. R. Veraart, M. C. E. Groot, C. Gooijer, H. Lingeman, N. H. Velthorst and U. A. Th. Brinkman, *Analyst*, 124, 115, **1999**.
- 60-M. Fillet, I. Bechet, V. Piete and J. Crommen, *Electrophoresis*, 20, 1907, **1999**.
- 61-S. Cherkaoui, J. L. Veuthey, *Journal of Chromatogr. A*, 874, 121, **2000**.
- 62-W. Zhu, G. Vigh, *J. Microcolumn Separations*, 12, 167, **2000**.
- 63-K. D. Altra, *J. Chromatogr. A*, 844, 371, **1999**.
- 64-A. M. Abushoffa, M. Fillet, A. C. Servais, P. Hubert and J. Crommen, *Electrophoresis*, 24, 343, **2003**.
- 65-S. C. Gabriela and T. R. Vincent, *Anal. Chem.*, 72, 3605, **2000**.
- 66-H. Bartsch, A. Eiper and H. Kopelent-Frank, *J. Pharma. Biomed. Anal.*, 20, 531, **1999**.
- 67-M. E. Abdel-Hamid, L. Novotny, H. Hamza, *J. Pharma. Biomed. Anal.*, 24, 587, **2001**.

- 68-M. Xiu-Sheng, G. K. Brenda and D. M. Chris, J. Chromatogr. A, 952, 139, **2002**.
- 69-M. Farre, I. Ferrer, A. Ginebreda, M. Figueras, L. Olivella, L. Tirapu, M. Vilanova and D. Barcelo, J. Chromatogr. A, 938, 187, **2001**.
- 70-M. E. Abdel-Hamid, J. Liq. Chrom & Rel. Technol., 23, 3095, **2000**.
- 71-A. Cappiello, M. Balogh, G. Famiglini, F. Mangani and P. Palma, Anal. Chem., 72, 3841, **2000**.
- 72-S. M. R. Stanely, N. A. Owens and J. P. Rodgers, J. Chromatogr. B, 667, 95, **1995**.
- 73-Y. Cheng, Z. Lu and U. Neue, Rapid Commun. Mass Spectrom., 15, 141, **2001**.
- 74-W. Ahrer, E. Scherwenk and W. Buchberger, J. Chromatogr. A, 910, 69, **2001**.
- 75-C. Desiderio and S. Fanali, J. Chromatogr. A, 895, 123, **2000**.
- 76-S. Heitmeier and G. Blaschke, J. Chromatogr. B, 721, 109, **1999**.
- 77-D. Loudon, A. Handley, S. Taylor, E. Linz, S. Miller and I. D. Wilson, Anal. Chem., 72, 3922, **2000**.
- 78-U. G. Sidelmann, I. Bjornsdottir, J. P. Shockcor, S. H. Hansen, J. C. Lindon and J. K. Nicholson, J. Pharm. Biomed. Anal., 24, 569, **2001**.
- 79-G. J. Christain and J. E. O'Reilly, Instrumental analysis, 2nd Edition, Prentice-Hall, Inc., A. Simon & Schuster Company, New Jersey, **1986**.
- 80-D. A. Skog and J. J. Leary, Principle of instrumental analysis, 4th Edition, Saunder College Publishing, Florida, **1992**.
- 81-L. G. Hargis, Analytical chemistry: Principle and Techniques, Prentice-Hall, Inc., New Jersey, **1988**.
- 82-J. R. Jezorek and H. Freiser, Anal. Chem., 119, 2795, **1979**.
- 83-D. A. Skoog, D. M. West and F. G. Holler, Fundamentals of Analytical Chemistry, 7th Edition, Saunders College Publishing U.S.A., **1996**.
- 84-L. Y. Snyder and J. J. Kirkland, Introduction to Modern Liquid Chromatography, John Wiley & Sons, New York, **1974**.
- 85-F. P. Colin and A. S. Sheila, Contemporary Practice of Chromatography, Elsevier Science publishers, New York, **1984**.
- 86-P. E. Andern, M. R. Emmett and R. M. Caprioli, J. Am. Soc. Mass Spectrom., 5, 867, **1994**.
- 87-D. L. Vollmer and M. L. Gross, J. Mass Spectrom., 30, 113, **1995**.
- 88-L. Grotjahn and L. C. E. Taylor, Org. Mass Spectrom., 20, 146, **1985**.
- 89-J. B. Fenn, M. Mann, C. K. Meng, S. F. Wong and C. M. Whitehouse, Science,

246, 64, **1989**.

90-M. Karas and F. Hillenkamp, *Anal. Chem.*, 60, 2299, **1988**.

91-E. Nordhoff, R. Cramer, M. Karas, F. Hillenkamp, F. Kirpekar, K. Kristiansen and P. Roepstorff, *Nucleic acids Res.*, 21, 3347, **1993**.

92-K. J. Wu, T. A. Schaler and C. H. Becker, *Anal. Chem.*, 66, 1637, **1994**.

93-E. Nordhoff, F. Kirpekar and Roepstorff, *Mass Spectrom. Rev.*, 15, 76, **1996**.

94-E. Bayer, T. Bauer, K. Schmeer, K. Bleicher, M. Maler and H. J. Gaus, *Anal. Chem.*, 66, 3858, **1994**.

95-A. Deroussent, J. P. Le Caer and A. Gouyette, *Rapid Commun. Mass Spectrom.*, 9, 1, **1995**.

96-J. P. Barry, P. Vouros, A. Van Schepdael and S. J. Lay, *Mass Spectrom.*, 30, 993, **1995**.

97-D. M. Reddy, R. A. Rieger, M. C. Torres and C. R. Iden, *Anal. Biochem.*, 220, 200, **1994**.

98-R. J. Boughtflower, T. Underwood, C. J. Paterson, *Chromatographia* 40, 329, **1995**.

99-E. Rapp, E. Bayer, *J. Chromatogr. A*, 887, 367, **2000**.

100-J. Hierten, *J. Chromatogr.* 473, 273, **1989**.

101-C. Vandecasteele and C. B. Block, *Modern Methods for Trace Element and Determination*, John Wiley & Sons, Inc., New York, **1995**.

102-W. M. A. Niessen and L. Van der Greef, *Liquid chromatography-mass spectrometry: principles and applications*, New York, 58, p 29, **1992**.

103-J. R. Chapman, *Practical Organic Mass Spectrometry*, Wiley, London, UK **1986**.

104-J. B. Lambert, H. F. Shurvell, D. Lightner and R. G. Cooks, *Introduction to organic spectroscopy*, MacMillan Publishing, Company, New York, NY, USA, p.313, **1987**.

105-F. W. Karasek and R. E. Clement, *Basic gas chromatography-mass Spectrometry*, Elsevier Science Publishing, Amsterdam, the Netherlands **1988**.

106-D. I. Carroll, I. Dzidic, R. N. Stillwell, K. D. Haegele and E. C. Hornig, *Anal. Chem.*, 47, 2369, **1975**.

107-R. M. Caprioli, T. Fan and J. S. Cottrell, *Anal. Chem.*, 58, 2949, **1986**.

108-M. Yamashita and J. B. Fenn, *J. Chem. Phys.*, 80, 4451, **1984**.

109-R. B. Cole, *Electrospray Mass Spectrometry: Fundamentals, Instrumentation*

- & Applications, John Wiley & Sons, Inc., New York, **1997**.
- 110-K. B. Tömer, M. A. Moseley, L. J. Deterding and C. E. Parker, *Mass Spectrom. Rev.*, **13**, p. 431, **1994**.
- 111-W. M. A. Niessen, *J. Chromatogr. A*, **794**, 407, **1998**.
- 112-J. F. Banks, J. P. Quinn and C. M. Whitehouse, *Anal. Chem.*, **66**, 3688, **1994**.
- 113-E. C. Huang, T. Wachs, J. J. Canboy and J. D. Henion, *Anal. Chem.*, **62**, 713A, **1990**.
- 114-A. P. Bruins, *Mass Spectrom. Rev.*, **10**, 53, **1991**.
- 115-P. Kebarle and Y. Ho, On the Mechanism of Electrospray Mass Spectrometry, in R. B. Cole (Editor), *Electrospray Mass Spectrometry: Fundamentals, Instrumentation & Applications*, John Wiley & Sons, Inc., New York, p. 3, **1997**.
- 116-M. Dole, L. L. Mack, R. L. Hines, R. C. Mobley, L. D. Ferguson and M. B. Alice, *J. Chem. Phys.*, **49**, 2240, **1968**.
- 117-J. V. Iribarne and A. Thomson, *J. Chem. Phys.*, **64**, 2287, **1976**.
- 118-R. D. Smith, C. J. Barinaga and H. R. Udseth, *Anal. Chem.*, **60**, 1948, **1988**.
- 119-R. N. Warriner, A. S. Craze, D. E. Games and S. L. Lane, *Rapid Commun. Mass Spectrom.*, **12**, 1143, **1998**.
- 120-E. D. Lee, W. M. Mück, J. D. Henion and T. R. Covey, *J. Chromatogr.*, **474**, 21, **1988**.
- 121-J. H. Wahl and R. D. Smith, *J. Cap. Elect.*, **1**, 62, **1994**.
- 122-D. C. Gale and R. D. Smith, *Rapid. Commun. Mass Spectrom.*, **7**, 1017, **1993**.
- 123-J. A. McClosky, *Mass spectrometry*, Academic Press Inc., San Diego, **1990**.
- 124-<http://www.aeat.com/pes/basys/manual/1le/vol-I.htm>
- 125-U. R. Kunze, *Basic of the quantitative analysis*, 3. revised edition, publishing house Stuttgart, **1990**.
- 126-J. S. Fritz, G. H. Schenk, *Quantitative Analytical Chemistry*, 5th Edition, Prentice Hall, Englewood Cliffs (NJ), **1987**.
- 127-VOGEL's *Textbook of Quantitative Chemical Analysis*, Longman Group UK, **1989**.
- 128-MACHEREY-NAGEL, *Sample Preparation Solid Phase Extraction and Membrane Filtration* [instruction manual].
- 129-J. T. BAKER, *Solid Phase Extraction for Sample Preparation* [instruction manual].

- 130-SULPELCO, *The Sulpelco Guide to Solid Phase Extraction* [instruction manual].
- 131-WATERS, *SPE Applications Guide and Bibliography Sixth Edition* [instruction manual].
- 132-K. C. Van Horne , *Handbuch Zur Festphasenextraktion*, ict GmbH, Bad Homburg, **1993**.
- 133-I. Liska, J. Krupik and P. A. Leclercq, *J. High Resolut. Chromatogr.*, 12, 577, **1989**.
- 134-C. W. Huck and G. K. Bonn, *J. Chromatogr.*, 885, 51, **2000**.
- 135-R. Pirker, Disseretation, Innsbruck Unuiv., Austria, **2003**.
- 136-R. Voigt, pharmaceutical technology for study and occupation, edition, Ullstein Mosby GmbH & CO acute. KG, Berlin/Wiesbaden, **1995**.
- 137-P. Zaborsky, Diplomarbeit, Innsbruck, Univ., Austria, **2003**.
- 138-J. Klimes, J. Sochor, M. Zahradnicek, J. Sedlacek, *J. Chromatogr.* 584, 221, **1992**.
- 139-F. Lapique, P. Netter, B. Bannwarth, P. Trechot, P. Gillet, H. Lambert and R. J. Royer, *J. Chromatogr. A*, 496, 301, **1989**.
- 140-L. R. Snyder, J. J. Kirkland, J. L. Glajch, *practecal HPLC Method Development*, Wiley, New York, **1997**.
- 141-J. W. Dolan, L. R. Snyder, R. C. Wolcott, P. Haber, T. Bazczek, R. Kaliszan, L. C. Sander, *J. Chromatogr. A*, 857, 41, **1999**.
- 142-J. W. Dolan, *LC-GC Int* 9, 130, **1996**.
- 143-U. D. Neue *HPLC columns: theory, technology, and practice*, John Wiley & Sons, New York, USA, **1997**.
- 144-<http://www.mac-mod.com/tr/07031-tr.html> (October **2003**).
- 145-The United State Pharmacopeia The National Formulary, USP XXII. United States Pharmacopeial Convention, Rock-Ville, MD, 1990.
- 146-<http://www.metachem.com/Manuals/Care/colcare2.htm> (October **2003**).
- 147-<http://www.ionsource.com/tutorial/capillary/automate.htm> (October **2003**).
- 148-D. R. Baker, *Capillary Electrophoresis*, A wiley-Interscience Publication, John Wiley & Sons, Inc., New York, **1993**.
- 149-N. A. Guzman, ("Capillary Electrophoresis Tecnology") *Chromatographic Science*, 64 (Editor, J. Cazes), Marcel Dekker, Inc., New York, **1993**.
- 150-R. Wenberger, *Practeical Capillary Electrophoresis*, Academic Press, Inc., London, **1993**.
- 151-R. Kuhn and S. Hffstetter-Kuhn , *Capillary Electrophoresis: Principlees*

- and Practice, Springer-Verlag, Berlin, Heidelberg, **1993**.
- 152-S. F. Y. Li, "Capillary Electrophoresis", J. Chromatogr. Library, 52, Elsevier Science B.V. **1993**.
- 153-P. Jandik, and G. Bonn, Capillary electrophoresis of small molecules and ion; VCH Publishers, New York, **1993**.
- 154-H. Nishi. and S. Terabe., J. Chromatogr. A, 735, 3, **1996**.
- 155-M. M. dittmann and G.P. C. Rozing, J. Chromatogr. A, 744, 63, **1996**.
- 156-Q. Tang and M. L. J. Lee, J. Chromatogr. A, 887, 265, **2000**.
- 157-S. Terab, K. Otsuka, K. Ichikawa, A. Tsuchiya, T. Ando, Anal. Chem., 56, 111, **1984**.
- 158-S. Terab, K. Otsuka, T. Ando, Anal. Chem., 57, 834, **1985**.
- 159-M. G. Khaledi, High Performance Capillary Electrophoresis, Theory, Techniques, and Applications, A Wiley-Interscience Publication, John Wiley & Sons, INC. New York, **1998**.
- 160-A. Paulus, Angew. Chem., Int. Ed. Engl., 35, 857, **1996**.
- 161-B. Chankvetadze, Capillary electrophoresis in Chiral analysis, west Sussex, England, **1997**.
- 162-M. J. Rosen, Surfactants and Interfacial phenomena, Wiley, New York **1988**.
- 163-K. D. Altra, LC.GC. Intl., 6, 164, **1993**.
- 164-K. Lee and G. S. Heo, J. Chromatogr., 559, 317, **1991**.
- 165-H. Watzig and C. Detta, J. Chromatogr., 636, 13, **1993**.
- 166-F. A. Thomas-Barberan, Phytochemical analysis, 6, 177, **1995**.
- 167-K. D. Lukacs and J. W. Jorgenson, HRC-J. High Res. Chromatogr., 8, 407, **1985**.
- 168-P. Coufal, K. Stulik, H. A. Claessens and C. A. Cramers, J. High Res. Chromatogr., 17, 325, **1993**.
- 169-G. Mandrup, J. Chromatogr., 604 267, **1992**.
- 170-A. S. Cohen, S. Terabe and Z. Deyl "Capillary Electrophoretic Separations of Drugs" Amsterdam. The Netherlands **1996**.)
- 171-K. D. Altria, Capillary Electrophoresis Guidebook: Principles, Operation and Application, 1st edition, Humana Press Inc., New Jersey **1996**.
- 172-S. Bookerd, M. R. Delaevernier and Y. Michotte, J. Chromatogr. A, 670, 209, **1994**.

- 173-B. R. Thomas and S. Ghodbane J. Liq. Chromatogr. 16, 1983, **1993**.
- 174-E. V. Dose and G. A. Guiochon, Anal. Chem., 63, 1154, **1991**.
- 175-J. Prunonosa, R. Obach, A. Diez-Cascon and L. Gouesclou, J.Chromatogr., 581, 219, **1992**.
- 176-K. D. Altria, J. Chromatogr., 646, 245, **1993**.
- 177-K. D. Altria et al J. Chromatogr., 641, 147, **1993**.
- 178-K. D. Altria and D. R. Rudd, Chromatographia, 41, 325, **1995**.
- 179-P. E. Jackson and P. R. Haddad, J. Chromatogr., 640, 481, **1993**.
- 180-K. D. Altria and Y. L. Chanter, J. Chromatogr., 652, 459, **1993**.
- 181-M. E. Swatz, J. R. Mazzeo, E. R. Grover and P. R. Brown, J. Chromatogr. A, 735, 303, **1996**.
- 182-C. X. Zhang, F. von Heeren and W. Thormann, Anal. Chem., 67, 2070, **1995**
- 183-A. Schmutz and W. Thormann, Electrophoresis, 15, 51, **1994**.
- 184-K. D. Altria, Methods in Molecular Biology, Vol 52 Capillary Electrophoresis Guidebook, Totowa, New Jersey, USA, **1996**.
- 185-S. Fujiwara and S. Honda, Anal. Chem. 59, 2773, **1987**.
- 186-AOAC, Peer verified method program, Manual on policies and procedures, Arlington, VA, USA, November **1993**.
- 187-K. A. Connors, G. L. Amidon and L. Kennon, Chemical Stability of pharmaceuticals, Wiley, NY, **1978**.
- 188-A. N. Matrin, J. Swarbrick and A. Cammarata, Physical Pharmacy, second ed., Henry Kimpton, London, **1969**.
- 189-J. T. Carstensen, Drug Stability-Principles and Practices, second ed., Marcel Dekker, New York, pp. 17, **1995**.
- 190-M. B. Henry, O. L. Charles and R. L. wait, "Physical and Technical Pharmacy" MC Graw-Hill Book Co., Inc., New York, Toronto, London, 621, **1963**.
- 192-A. T. Florence and D. Attwood., "Physicochemical Principles of Pharmacy", 2ndEd., Macmillan Press Ltd, London, 81, **1988**.
- 192-I. W. James, "Pharmaceutical preformulation", The Physicochemical properties of Drug Substances, Ellis Horwood Ltd, 152, **1988**.
- 193-L. C. Schroeter and T. Higuchi; J. Am.Pharm.Ass., 47, 462, **1958**.
- 194-J. R. D. Mecromick; J. Am.Chem.Soc., 79, 2849, **1957**.

- 195-N. Thyagarajapuram and K.S. Alexander, J. Liq. Chroma. & Rel. Tech., 26, 1315-1326, **2003**.
- 196-I. Racz "Drug Formulation", John Wiley & Sons, New York, Tronto and Singapore; 28, **1989**
- 197-S. Siggia "Quantitative Organic Analysis Via Functional Group", Wiley Interscience N.Y., **1972**.
- 198-The British Pharmacopeia, London, Her Majesty's stationary office, 35, **2000**.
- 199-The European Pharmacopoeia', Supplement 2000, 329,330, **2000**.
- 200-J. R. Posac, M. D. Vazquez, M. L. Tascon, J. A. Acuna, C. de laFuente, E. Velasco and P. S. Batanero, Talanta, 42, 293, **1995**.
- 201-N. Y. Hasan, M. Abdel-Elkawy, B. E. Elzeany and N. E. Wagieh, Farmaco, 58, 91, **2003**.
- 202-N. M. El Kousy, J. Pharm. Biomed. Anal., 20, 185, **1999**.
- 203-Z. Jinhui, X. Yungen and C. Yuying, Zhongguo Yaoke Daxue Xuebao 30, 34, **1999**.
- 204-N. H. Zawilla, M. A. Mohammad, N. M. El Kousy and S. M. El-Moghazy Aly, J. Pharm. Biomed., 27, 243, **2002**.
- 205-H. S. Lee, C. K. Jeong, S. J. Choi, S. B. Kim, M. H. Lee, G. I. Ko and D. H. Sohn, J. Pharm. Biomed. Anal., 23, 775, **2000**.
- 206-H. Abu-Yossef, Disseretation, Cairo Univ., Faculty of Pharmacy, Egyp, **1997**.
- 207-J. Krzek. M. Starek, J. Pharm. Biomed. Anal., 28, 227, **2002**.
- 208-F. Gottfried, F. Werner, L. Dieter, P. Werner, C. Klaus, O. Eberhard and C. Wolfgang. (VEB Arzneinmittelwerk Dresden, Ger (East) (**1990**), Coden: GEXXA8 DD 283500 A7 19901017 patent written in german.
- 209-T. A. Lee A Beginner's Guide to Mass Spectral Interpretation, John Wiley & Sons New York, USA, **1998**.

LIST OF TABLES

	Page
Table I.1 Data of studied NSAIDs.....	3
Table I.2 Spectrophotometric methods.....	5
Table I.3 HPLC methods.....	8
Table I.4 CE methods.....	13
Table I.5 LC-MS methods.....	17
Table II.1 Characteristics of normal-and reversed-phase liquid chromatography.....	24
Table II.2 Optimized equipment parameters for LC-ESI or APCI)-MS (ion-trap).....	43
Table II.3 Optimized equipment parameters for LC-APCI-MS(TSQ).....	44
Table II.4 The structure of NSAIDs studied by chromatographic analysis.....	45
Table II.5 Gradient program.....	48
Table II.6 Effect of mobile phase on peak symmetry of NSAIDs.....	49
Table II.7 Analytical parameters for separation of 10 NSAIDs using HPLC-UV.....	53
Table II.8 Reproducibility and recovery rates of the HPLC-UV method for 10 NSAIDs and pharmaceuticals.....	55
Table II.9a Comparison between SPE and LLE for the extraction of NSAIDs in spiked with plasma.....	58
Table II.9b GMA/DVB irregular particles for solid phase extraction.....	58
Table II.10 Analytical parameters for separation mixture of NSAIDs analytes spiked with whole blood, erythrocytes and plasma.....	59
Table II.11 Calibration parameters, reproducibility and limits of detection of 8 NSAIDs using μ -HPLC-UV.....	64
Table II.12 Reproducibility and recovery data of NSAIDs using μ -HPLC-UV.....	65
Table II.13 Comparison of the product ion for selected drugs using either an APCI or an ESI (-Ve) mode.....	70
Table II.14 Calibration curve parameters and (LOD) of NSAIDs by LC-MS using two different interfaces for ionization.....	71
Table II. 15 Recovery percentages of NSAIDs from quaternary laboratory made mixtures (n=3) using LC-MS (APCI).....	72
Table II.16 Recovery percentages of the studied analytes (NSAIDs) expressed as % with respect to the labile claim using LC-MS (APCI).....	72
Table II.17 Comparison of the identified product ion for the selected NSAIDs using an APCI interface (+Ve) and (-Ve) mode.....	77
Table II.18 Analytical parameters for separation of 8 NSAIDs using LC-MS and recovery of applied pharmaceuticals.....	80
Table. III.1The data and chemical structure of NSAIDs analytes separated by MEKC.....	92
Table.III.2 Intra-day of migration time and peak area of the studied NSAIDs analytes.....	101
Table III.3 Inter-day reproducibility of migration time and peak area of the studied NSAIDs.....	101
Table III.4 (A, B, C) Average values, SD and RSD%of peak area for the studied NSAIDs analytes at five different concentrations.....	102
Table. III.5 Standards for calibration of studied NSAIDs using MEKC.....	104
Table. III.6 Parameters of the calibration curves of the MEKC method.....	104
Table. III.7 LOD and LOQ of the investigated analytes using MKEC.....	106
Table III.8 Calibration parameters, extraction recoveries and limit of detection (LOD) of NSAIDs in spiked plasma.....	109
Table III.9(a-e) Recoveries and precision of the MEKC method for the determination of pharmaceutical formulations.....	112
Table III.10 Limit of detection of NSAIDs determined via CE(MKEC) and HPLC.....	117
Table IV.1 The time periods for injection AC samples onto HPLC system.....	126
Table IV.2 Parameters analysis of aceclofenac with its degradation by using HPLC.....	132
Table IV. 3 Determination of aceclofenac using HPLC (in presence mixture of 20 μ g ml ⁻¹ of diclofenac and 20 μ g ml ⁻¹ of 1-(2,6-dichlorophenyl)-2-indolinone.....	132
Table IV.4 Determination of diclofenac using HPLC (in presence mixture of 20 μ g ml ⁻¹ of aceclofenac and 20 μ g ml ⁻¹ of 1-(2,6-dichlorophenyl)-2-indolinone.....	133
Table IV.5 Determination of 1-(2,6-dichlorophenyl)-2-indolinone using HPLC (in presence mixture of 20 μ g ml ⁻¹ of aceclofenac and 20 μ g ml ⁻¹ of diclofenac).....	133
Table IV.6 Determination of aceclofenac in pharmaceutical formulation (Beofenac tablets) using HPLC Method.....	134
Table IV.7 Kinetics parameters for the degradation of aceclofenac in 0.1 M HCl. 0.1	

M NaOH and phosphate buffer (pH 7.5) at 25, 40, 60°C (derived from first order plots).....	<u>141</u>
Table IV. 8 Summary of regression line equation and activation energy (E_a) of kinetics degradation for aceclofenac in various solvents as derived from Arrhenius plots.....	<u>142</u>

LIST OF FIGURES

Fig. II.1	Parameter for determination of resolution and selectivity.....	19
Fig. II.2	Effect of different separation conditions (k , N , α) on HPLC resolution.....	21
Fig. II.3	Influence of different mass transfer coefficients to column plate height.....	23
Fig. II.4	Structure of HPLC system (low pressure gradient system).....	25
Fig. II.5	Structure of the μ -HPLC-System.....	26
Fig. II.6	Schematic of an API interface for LC-MS.....	28
Fig. II.7	Diagram of an Atmospheric Pressure Chemical Ionization (APCI).....	29
Fig. II.8	Major processes involved in the formation of gas-phase ions by ESI operated in the negative ion mode.....	30
Fig. II.9	structure of a SPE column.....	35
Fig. II.10	diagram of the basic steps of a solid phase extraction.....	35
Fig. II.11	HPLC-UV chromatograms of NSAID standard mixture using different mobile phase systems, stationary phase, Spherisorb C ₁₈ , 150 mm $\times$ 4.6 mm, 5 μ m; 80 Å; mobile phase, (a) H ₂ O/ACN, (b) NH ₄ OAC/ACN; gradient, 0 min 95% A, 0 min to 10 min from 95% A to 20% A, 12 min to 14 min 20% A to 95% A; flow rate, 1 mL/min; temperature, 25°C; injection. volume., 20 μ L; detection, UV, 270 nm; peak assignment: 1 salicin, 2 salicylic acid, 3 tenoxicam, 4 ketorolac, 5 tolmetin, 6 piroxicam, 7 naproxen, 8 flurbiprofen, 9 diclofenac, 10 ibuprofen.....	47
Fig. II.12	HPLC-UV chromatograms of NSAID standard mixture using NH ₄ OAC/ACN gradient at different pH: (a) 6.7, (b) 4.7, (c) 3.7, (d) 3.0; stationary phase, gradient, flow rate, injection volume, detection and peak assignment see Fig II.11.....	50
Fig. II.13	HPLC-UV chromatograms of NSAID standard mixture using different stationary phases; (a) Bischoff, ProntoSIL 120, C ₁₈ (250 mm $\times$ 2 mm, 5 μ m; 120 Å); (b) Nucleosil C ₁₈ (250 mm $\times$ 3 mm, 5 μ m; 120 Å); (c) Spherisorb C ₁₈ (150 mm $\times$ 4.6 mm, 5 μ m; 80 Å); mobile phase NH ₄ OAC, pH 3.7/ACN; flow rate, (a) 0.4 mL/min (b) 0.4 mL/min (c) 1 mL/min; temperature, detection and peak assignment see Fig. II.5.....	51
Fig. II.14	HPLC-UV chromatograms of a NSAID standard mixture using NH ₄ OAC (pH 7.3) /ACN gradient at different temperatures: (a) 25°C, (b) 35°C, (c) 45°C, (d) 55°C; stationary phase, gradient, flow rate, injection volume, detection and peak assignment see Fig. II.11.....	52
Fig. II.15	Extraction recovery of NSAIDs analytes spiked with blood using different extraction solvents.....	56
Fig. II.16	HPLC-UV chromatograms of NSAID standard mixture (pure standard) (a), blank (b) and of plasma spiked with standard (c); stationary phase, mobile phase, gradient, injection volume, detection see Fig. II.11 (pH = 3.7); peak assignment: 1 salicylic acid (internal standard), 2 tenoxicam, 3 tolmetin, 4 naproxen, 5 diclofenac.....	57
Fig. II.17	μ HPLC-UV chromatogram of NSAID standard mixture on a ProntoSIL 120 C ₁₈ stationary phases fixed by; (a) frit ProntoSIL 120 C ₁₈ (80 mm $\times$ 0.2 mm, 3 μ m; 120 Å), (b) encapsulated ProntoSIL 120 C ₁₈ (80 mm $\times$ 0.2 mm, 3 μ m; 120 Å) mobile phase KH ₂ PO ₄ , pH 2.2/ACN; gradient, 0 min, 90% A, 0 min to 10 min 90% A to 20% A, 12 min to 14 min 20% A to 90% A; flow rate: 2.2 μ L/min (175 μ L/min) temperature 50 °C; injection volume 0.5 μ L; UV-detection at 270 nm; peak assignment: 1 tenoxicam, 2 salicylic acid, 3 ketorolac, 4 piroxicam, 5 tolmetin, 6 naproxen, 7 flurbiprofen, 8 diclofenac.....	61
Fig. II.18	μ HPLC-UV chromatogram of NSAID standard mixture using different pH of mobile phase (a) 3, (b) 2.2, (c) 1.8, on stationary phase encapsulated ProntoSIL 120 C ₁₈ (80 mm $\times$ 0.2 mm, 3 μ m; 120 Å), mobile phase, gradient, temperature, flow rate, injection volume, peak assignment, see Fig. II.11.....	62
Fig. II.19	μ HPLC-UV chromatogram of NSAID standard mixture at different temperatures; (a) 30°C, (b) 40°C, (c) 50°C; stationary phase encapsulated ProntoSIL 120 C ₁₈ (80 mm $\times$ 0.2 mm, 3 μ m; 120 Å), mobile phase, gradient, flow rate, injection volume, detection, and peak assignment see Fig. II.11.....	63
Fig. II.20	Influence of mobile phase composition and addition of additive on MS-detection of NSAIDs on using APCI interface and T-piece for sheath liquid.....	67
Fig. II.21a	LC-APCI-MS chromatogram of a NSAID standard mixture; stationary phase, Spherisorb C ₁₈ , 150 mm $\times$ 4.6 mm, 5 μ m; 80 Å; mobile phase, NH ₄ OAC/ACN; gradient, 0 min 95% A, 0 min to 10 min from 95% A to 20% A, 12 min to 14 min 20% A to 95% A; flow rate, 1 mL/min; temperature, 25°C; injection, volume, 20 μ L; detection, UV, 270 nm; peak assignment: 1 salicin, 2 salicylic acid, 3 naproxen, 4 flurbiprofen, 5 ibuprofen.....	68

Fig. II.21b LC-APCI-MS (ion trap) fragment ion of total ion chromatogram (TIC) of a mixture of salicin, salicylic acid, flurbiprofen and ibuprofen and the extracted SIM chromatograms of the individual components.....	69
Fig. II.22 LC-APCI-MS(TSQ) chromatogram of NSAID standard mixture; stationary phase, Hypersil C ₁₈ (100 mm × 1mm, 3 µm; 120 Å); mobile phase, NH ₄ OAc, pH 3.7/ACN; gradient 0 min, 99% A, 0 min to 10 min 99% A to 35% A, 12 min to 14 min 35% A to 99% A; flow rate, 150 µL/min; temperature, 45 °C; injection volumn, 5 µL, detection MS full scan; peak assignment: 1 salicylic acid, 2 tenoxicam, 3 ketorolac, 4 piroxicam, 5 tolmetin, 6 naproxen, 7 flurbiprofen, 8 diclofenac.....	74
Fig. II.23a LC-APCI-MS (TSQ) fragment ion of total ion chromatogram (TIC) of a mixture of salicin, salicylic acid, tenoxicam, ketorolac, piroxicam, tolmetin, naproxen, flurbiprofen and diclofenac and the extracted SIM chromatograms of the individual components.....	75
Fig. II.23b LC-APCI-MS (TSQ) fragment ion of total ion chromatogram (TIC) of a mixture of salicin, salicylic acid, tenoxicam, ketorolac, piroxicam, tolmetin, naproxen, flurbiprofen and diclofenac the extracted SIM chromatograms of the individual components.....	76
Fig. III.1 Schematic representation of six modes of capillary electrophoresis separation.....	85
Fig. III.2 Schematic representation of CE instrument.....	88
Fig. III.3 Influence of Na ₂ HPO ₄ concentration on analysis time, efficiency and resolution , of , NSAIDs ; Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic; Detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C; Buffer: 50 mM SDS; 20 mM β-cyclodextrin.....	93
Fig. III.4 Influence of the SDS concentration on analysis time efficiency and resolution of mixture NSAIDs Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic; Detection <u>UV at 200 nm</u> ; U = +25 kV, I = 58-63 µA, T = 24-26°C; Buffer 20 mM Na ₂ HPO ₄ , 20 mM β-cyclodextrin.....	94
Fig. III.5 Influence of β-CD concentration on analysis time efficiency and resolution of NSAIDs Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic; Detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C; Buffer 50 mM SDS, 20 mM Na ₂ HPO ₄	94
Fig. III.6 Effect of buffer pH on separation mixture of NSAIDs analytes. Buffer; 50 mM SDS, 20 mM Na ₂ HPO ₄ and 20 mM β-CD; Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic; Detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C.....	95
Fig. III.7 Influence of UV detection of NSAIDs. Buffer; 50 mM SDS, 20 mM Na ₂ HPO ₄ and 20 mM β-CD; Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic (20psi) ; Detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24- 26°C.....	96
Fig. III.8 Influence of applied voltage (U) on electrophoretic separation of NSAIDs; Buffer: 50 mM SDS, 20 mM Na ₂ HPO ₄ and 20 mM β-CD; pH 9; Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Detection <u>UV at 200 nm</u> ; Injection: 5 sec hydronamic (20psi); T = 24-26°C.....	98
Fig. III.9 Effect the sample concentration on RSD% of peak area.....	103
Fig. III.10 Calibration curves for the investigated NSAIDs by using MKEC.....	105
Fig. III.11 Electropherogram of a NSAIDs at the LOD (A) and LOQ (B). Buffer 20 mM Na ₂ HPO ₄ , 50 mM SDS and 20 mM β-CD, pH 9.00. Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; injection: 5 sec hydronamic; detection <u>UV at 200 nm</u> ; U = +25 kV, I = 58-63 µA, T = 24-26°C; for concentration see Table III.7.....	107
Fig. III.12 Calibration curves of NSAIDs spiked in plasma by using MKEC.....	110
Fig. III.13 Electropherogram of a mixture NSAID standard (A), free plasma (B) and a mixture of NSAID standard spiked in plasma (C). CE conditions: Buffer 20 mM Na ₂ HPO ₄ , 50 mM SDS and 20 mM β-CD, pH 9.00; capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; injection: 5 sec hydronamic; detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C.....	111
Fig. III.14 Electropherogram of the separation of the Mixture of NSAIDs analytes in Pharmaceutical formulation; 50 µg/ml for flurbiprofen, 200 µg/ml for naproxen and 25 µg/ml for (piroxicam, diclofenac sodium and indomethacin). Under CE conditions, Buffer 20 mM Na ₂ HPO ₄ , 50 mM SDS and 20 mM β-CD, pH 9.00; Capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec (20 psi); detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C.....	115
Fig. III.15 Separation of NSAIDs using; MEKC (A) and HPLC (B) Electrophoretic conditions: Buffer 20 mM Na ₂ HPO ₄ , 50 mM SDS and 20 mM β-CD, pH 9.00; capillary: Uncoated fused silica, L = 58 cm, L _{eff} = 50 cm, i.d. 50 µm; Injection: 5 sec hydronamic (20psi) ; detection UV at 200 nm; U = +25 kV, I = 58-63 µA, T = 24-26°C and chromatographic conditions: stationary phase, Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase, KH ₂ PO ₄ /ACN; gradient, 0 min 95% A, 0 min to 10 min from 95% A to 20% A, 12 min to 14 min 20% A to 95% A; flow rate, 1mL/min; temperature, 25°C; injection, volume, 20 µL; detection, UV, 270 nm.....	116
Fig. III.16 Analysis time of NSAIDs determined via MEKC and HPLC.....	117

Fig. IV.1 A Plot corresponding the Arrhenius equation.....	121
Fig. IV.2 Chemical structure of aceclofenac.....	124
Fig. IV.3 Absorption spectra of aceclofenac ⁽¹⁾ , diclofenac ⁽²⁾ and 1-(2,6- dichlorophenyl)-2-indolinone ⁽³⁾ , recorded directly HPLC-UV-PDA during acid degradation.....	128
Fig. IV.4 HPLC chromatograms of aceclofenac and its degradation products obtained using different separation systems of mobile phase (isocratic and gradient) stationary phase, Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase NH ₄ OAC/ACN; temperature, 25°C; injection. volume., 20 µL; detection, UV, 270 nm; peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone.....	129
Fig. IV.5 Calibration curves for the determination of aceclofenac and its degradation products using HPLC a = aceclofenac, b = diclofenac, c = 1-(2,6- dichlorophenyl)-2-indolinone.....	130
Fig. IV.6 HPLC chromatograms of development of the degradation of aceclofenac at 0 (a), 12 (b) and 24 (c) hours in ethanolic solution at 40°C, stationary phase, column Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase NH ₄ OAC/ACN; temperature, 25°C; injection. volume., 20 µL; detection, UV, 246 nm; peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone.....	135
Fig. IV.7 HPLC chromatograms of development of the degradation of aceclofenac at 0 (a), 4 (b) and 24 (c) hours in phosphate buffer pH 7.5, at 40°C, stationary phase, column Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase NH ₄ OAC/ACN; temperature, 25°C; injection. volume., 20 µL; detection, UV, 246 nm; peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone.....	136
Fig. IV.8 HPLC chromatograms of development of the degradation of aceclofenac at 0 (a), 4 (b) and 24 (c) hours in acid solution, at 40°C, stationary phase, column Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase NH ₄ OAC/ACN; temperature, 25°C; injection. volume., 20 µL; detection, UV, 246 nm; peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone.....	137
Fig. IV.9 HPLC chromatograms for stability study of aceclofenac at 0 (a), 4 (b) and 24 (c) hours in 0.1 M NaOH development of third degradation product (1) (diclofenac methyl ester) and decomposition of the second degradation product (2) (diclofenac), stationary phase, column Spherisorb C ₁₈ , 150 mm × 4.6 mm, 5 µm; 80 Å; mobile phase NH ₄ OAC/ACN; temperature, 25°C; injection. volume., 20 µL; detection, UV, 246 nm; peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone, 4 diclofenac methyl ester.....	138
Fig. IV.10 First order plots for kinetic degradation of aceclofenac at 40°C in different solutions.....	140
Fig. IV.11 Arrhenius plots of aceclofenac in 0.1 M HCl and phosphate buffer (pH 7.5).....	140
Fig. IV.12 LC-MS Chromatograms of aceclofenac, chromatographic conditions: Stationary phase, Hypersil C ₁₈ (100 mm × 1mm, 3 µm; 120 Å); mobile phase, NH ₄ OAC, pH 3.7/ACN; gradient 0 min, 95% A, 0 min to 10 min 95% A to 35% A, 12 min to 14 min 35% A to 95% A; flow rate, 175 µL/min; temperature, 25 °C; injection volumn, 5 µL, detection MS full scan; peak assignment: 1 aceclofenac, MS conditions: APCI (positive ionization mode), vaporizer temperature, 350 °C, capillary temperature, 200 °C and current voltage, 1.74 kV.....	143
Fig. IV.13 LC-MS chromatograms for induced acid degradation of aceclofenac, chromatographic and MS conditions see Fig. IV.11, (a) total ion current, peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone, (b) fragment pattern from parent ion (m/z = 296.1) of diclofenac, (c) fragment pattern from parent ion of (m/z = 354.2) of aceclofenac, (d) fragment pattern from parent ion (m/z = 278.0) of 1-(2,6- dichlorophenyl)-2-indolinone.....	144
Fig. IV.14 Scheme 1 proposed pathway of acid-induced degradation of AC according LC-MS analysis.....	145
Fig. IV.15 LC-MS Chromatograms for induced base degradation of aceclofenac, chromatographic and MS conditions see Fig IV.11, (a) total ion current, peak assignment: 1 aceclofenac, 2 diclofenac, 3 1-(2,6- dichlorophenyl)-2-indolinone, 4 diclofenac methyl ester, (b) fragment pattern of parent ion (m/z = 296.1) of diclofenac, (c) fragment pattern of parent ion (m/z = 309.0) of diclofenac methyl ester, (d) fragment pattern of parent ion (m/z = 354.2) of aceclofenac, (e) fragment pattern of parent ion (m/z = 278.0) of 1-(2,6- dichlorophenyl)-2-indolinone.....	146
Fig. IV.16 Scheme 2. Proposed degradation pathway of AC according to LC-MS analysis.....	147